(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Exploring Programming Greatness: A Survey of \Easy to use Connection points\ - 2Which Film Has the Incomparable Melodic Score?
- 3The 15 Most Powerful Forerunners in Business
- 4What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- 5Manual for Vegetarian Protein Powder
- Experience Unrivaled Sound: Top Speakers You Really want to Hear
- Which game do you adore observing live? Vote!
- Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison
- Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
- Spots to Go Hang Floating
- Courageous Climbing: Trails and Stuff for Outside Lovers
- 6 Famous Urban communities for Shopping on the planet
- Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- Immortal Style: Closet Staples for Each Age
